annual EBITDA:
-$447.31M-$244.61M(-120.67%)Summary
- As of today (September 12, 2025), CRSP annual EBITDA is -$447.31 million, with the most recent change of -$244.61 million (-120.67%) on December 31, 2024.
- During the last 3 years, CRSP annual EBITDA has fallen by -$838.79 million (-214.26%).
- CRSP annual EBITDA is now -214.26% below its all-time high of $391.48 million, reached on December 31, 2021.
Performance
CRSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$128.47M+$15.22M(+10.59%)Summary
- As of today (September 12, 2025), CRSP quarterly EBITDA is -$128.47 million, with the most recent change of +$15.22 million (+10.59%) on June 30, 2025.
- Over the past year, CRSP quarterly EBITDA has increased by +$17.94 million (+12.26%).
- CRSP quarterly EBITDA is now -116.77% below its all-time high of $766.27 million, reached on June 30, 2021.
Performance
CRSP quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$437.24M+$17.94M(+3.94%)Summary
- As of today (September 12, 2025), CRSP TTM EBITDA is -$437.24 million, with the most recent change of +$17.94 million (+3.94%) on June 30, 2025.
- Over the past year, CRSP TTM EBITDA has dropped by -$125.48 million (-40.25%).
- CRSP TTM EBITDA is now -195.22% below its all-time high of $459.18 million, reached on June 30, 2021.
Performance
CRSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRSP EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -120.7% | +12.3% | -40.3% |
| 3 y3 years | -214.3% | +27.0% | +28.2% |
| 5 y5 years | -969.1% | -63.7% | -10000.0% |
CRSP EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -214.3% | +31.1% | -272.5% | +27.6% | -143.9% | +34.0% |
| 5 y | 5-year | -214.3% | +31.1% | -116.8% | +27.6% | -195.2% | +34.0% |
| alltime | all time | -214.3% | +31.1% | -116.8% | +27.6% | -195.2% | +34.0% |
CRSP EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$128.47M(-10.6%) | -$437.24M(-3.9%) |
| Mar 2025 | - | -$143.69M(+140.5%) | -$455.18M(+1.8%) |
| Dec 2024 | -$447.31M(+120.7%) | -$59.75M(-43.3%) | -$447.25M(+42.9%) |
| Sep 2024 | - | -$105.33M(-28.1%) | -$313.02M(+0.4%) |
| Jun 2024 | - | -$146.41M(+7.9%) | -$311.75M(+22.0%) |
| Mar 2024 | - | -$135.75M(-282.3%) | -$255.60M(+42.6%) |
| Dec 2023 | -$202.70M(-68.8%) | $74.48M(-171.6%) | -$179.28M(-52.8%) |
| Sep 2023 | - | -$104.06M(+15.3%) | -$379.46M(-16.2%) |
| Jun 2023 | - | -$90.26M(+51.9%) | -$452.76M(-15.9%) |
| Mar 2023 | - | -$59.44M(-52.7%) | -$538.49M(-17.0%) |
| Dec 2022 | -$648.99M(-265.8%) | -$125.69M(-29.1%) | -$648.99M(-2.1%) |
| Sep 2022 | - | -$177.37M(+0.8%) | -$662.73M(+8.8%) |
| Jun 2022 | - | -$175.99M(+3.6%) | -$608.89M(-282.6%) |
| Mar 2022 | - | -$169.93M(+21.9%) | $333.38M(-14.8%) |
| Dec 2021 | $391.48M(-213.4%) | -$139.44M(+12.9%) | $391.48M(-8.0%) |
| Sep 2021 | - | -$123.53M(-116.1%) | $425.72M(-7.3%) |
| Jun 2021 | - | $766.27M(-785.2%) | $459.18M(-219.1%) |
| Mar 2021 | - | -$111.83M(+6.3%) | -$385.58M(+11.7%) |
| Dec 2020 | -$345.25M | -$105.19M(+16.8%) | -$345.24M(+51.7%) |
| Sep 2020 | - | -$90.06M(+14.7%) | -$227.63M(-8009.4%) |
| Jun 2020 | - | -$78.50M(+9.8%) | $2.88M(-89.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$71.49M(-675.8%) | $27.59M(-46.6%) |
| Dec 2019 | $51.47M(-133.1%) | $12.41M(-91.2%) | $51.65M(-1123.8%) |
| Sep 2019 | - | $140.45M(-361.1%) | -$5.04M(-97.4%) |
| Jun 2019 | - | -$53.78M(+13.4%) | -$194.04M(+9.8%) |
| Mar 2019 | - | -$47.42M(+7.1%) | -$176.68M(+13.7%) |
| Dec 2018 | -$155.42M(+152.2%) | -$44.28M(-8.8%) | -$155.42M(+42.2%) |
| Sep 2018 | - | -$48.55M(+33.3%) | -$109.29M(+30.9%) |
| Jun 2018 | - | -$36.42M(+39.2%) | -$83.51M(+23.4%) |
| Mar 2018 | - | -$26.17M(-1511.6%) | -$67.69M(+10.0%) |
| Dec 2017 | -$61.62M(+348.4%) | $1.85M(-108.1%) | -$61.54M(-30.2%) |
| Sep 2017 | - | -$22.77M(+10.5%) | -$88.22M(+10.5%) |
| Jun 2017 | - | -$20.60M(+2.9%) | -$79.82M(+5.6%) |
| Mar 2017 | - | -$20.02M(-19.3%) | -$75.61M(+12.6%) |
| Dec 2016 | -$13.74M(-46.3%) | -$24.82M(+72.7%) | -$67.13M(+58.7%) |
| Sep 2016 | - | -$14.37M(-12.3%) | -$42.31M(+51.5%) |
| Jun 2016 | - | -$16.39M(+41.9%) | -$27.93M(+84.3%) |
| Mar 2016 | - | -$11.55M(+219.7%) | -$15.16M(+106.7%) |
| Dec 2015 | -$25.59M(+274.9%) | - | - |
| Jun 2015 | - | -$3.61M(-3.0%) | -$7.33M(+97.0%) |
| Mar 2015 | - | -$3.72M | -$3.72M |
| Dec 2014 | -$6.83M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual EBITDA?
- What is the all time high annual EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
- What is CRISPR Therapeutics AG quarterly EBITDA?
- What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
- What is CRISPR Therapeutics AG TTM EBITDA?
- What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
What is CRISPR Therapeutics AG annual EBITDA?
The current annual EBITDA of CRSP is -$447.31M
What is the all time high annual EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual EBITDA is $391.48M
What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
Over the past year, CRSP annual EBITDA has changed by -$244.61M (-120.67%)
What is CRISPR Therapeutics AG quarterly EBITDA?
The current quarterly EBITDA of CRSP is -$128.47M
What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly EBITDA is $766.27M
What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
Over the past year, CRSP quarterly EBITDA has changed by +$17.94M (+12.26%)
What is CRISPR Therapeutics AG TTM EBITDA?
The current TTM EBITDA of CRSP is -$437.24M
What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM EBITDA is $459.18M
What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
Over the past year, CRSP TTM EBITDA has changed by -$125.48M (-40.25%)